164 related articles for article (PubMed ID: 37752548)
1. Prevalence, one-year-incidence and predictors of carcinoid heart disease.
Mattig I; Franke MR; Pschowski R; Brand A; Stangl K; Knebel F; Dreger H
Cardiovasc Ultrasound; 2023 Sep; 21(1):18. PubMed ID: 37752548
[TBL] [Abstract][Full Text] [Related]
2. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
[TBL] [Abstract][Full Text] [Related]
3. Echocardiographic follow-up of treated patients with carcinoid syndrome.
Mansencal N; Mitry E; Bachet JB; Rougier P; Dubourg O
Am J Cardiol; 2010 Jun; 105(11):1588-91. PubMed ID: 20494667
[TBL] [Abstract][Full Text] [Related]
4. Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.
Buchanan-Hughes A; Pashley A; Feuilly M; Marteau F; Pritchard DM; Singh S
Neuroendocrinology; 2021; 111(1-2):1-15. PubMed ID: 32097914
[TBL] [Abstract][Full Text] [Related]
5. Assessment of patent foramen ovale in carcinoid heart disease.
Mansencal N; Mitry E; Forissier JF; Martin F; Redheuil A; Lepère C; Farcot JC; Joseph T; Lacombe P; Rougier P; Dubourg O
Am Heart J; 2006 May; 151(5):1129.e1-6. PubMed ID: 16644350
[TBL] [Abstract][Full Text] [Related]
6. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.
Denney WD; Kemp WE; Anthony LB; Oates JA; Byrd BF
J Am Coll Cardiol; 1998 Oct; 32(4):1017-22. PubMed ID: 9768727
[TBL] [Abstract][Full Text] [Related]
7. Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Dobson R; Cuthbertson DJ; Jones J; Valle JW; Keevil B; Chadwick C; Poston GP; Burgess MI
Neuroendocrinology; 2014; 99(2):85-93. PubMed ID: 24603343
[TBL] [Abstract][Full Text] [Related]
8. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka PA; Tajik AJ; Khandheria BK; Seward JB; Callahan JA; Pitot HC; Kvols LK
Circulation; 1993 Apr; 87(4):1188-96. PubMed ID: 7681733
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for the development and progression of carcinoid heart disease.
Bhattacharyya S; Toumpanakis C; Chilkunda D; Caplin ME; Davar J
Am J Cardiol; 2011 Apr; 107(8):1221-6. PubMed ID: 21296329
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract][Full Text] [Related]
11. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century.
Bhattacharyya S; Toumpanakis C; Caplin ME; Davar J
Am J Cardiol; 2008 Feb; 101(3):378-81. PubMed ID: 18237604
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with progression of carcinoid heart disease.
Møller JE; Connolly HM; Rubin J; Seward JB; Modesto K; Pellikka PA
N Engl J Med; 2003 Mar; 348(11):1005-15. PubMed ID: 12637610
[TBL] [Abstract][Full Text] [Related]
13. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
14. The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease.
Johnson KKN; Stemann Lau T; Mark Dahl Baunwall S; Elisabeth Villadsen G; Guldbrand Rasmussen V; Grønbaek H; Oksjoki RK; Dam G
J Neuroendocrinol; 2023 Oct; 35(10):e13327. PubMed ID: 37574797
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of the diagnosis and surgical management of carcinoid heart disease.
Namkoong J; Andraweera PH; Pathirana M; Munawar D; Downie M; Edwards S; Averbuj P; Arstall MA
Front Cardiovasc Med; 2024; 11():1353612. PubMed ID: 38572311
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease.
Mansencal N; McKenna WJ; Mitry E; Beauchet A; Pellerin D; Rougier P; Dubourg O
Am J Cardiol; 2010 Feb; 105(4):527-31. PubMed ID: 20152249
[TBL] [Abstract][Full Text] [Related]
17. Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort.
Grundmann E; Curioni-Fontecedro A; Christ E; Siebenhüner AR
BMC Cancer; 2023 Apr; 23(1):338. PubMed ID: 37055717
[TBL] [Abstract][Full Text] [Related]
18. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
19. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.
Zuetenhorst JM; Bonfrer JM; Korse CM; Bakker R; van Tinteren H; Taal BG
Cancer; 2003 Apr; 97(7):1609-15. PubMed ID: 12655516
[TBL] [Abstract][Full Text] [Related]
20. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
